BioWorld International Correspondent
PARIS - The initial public offering launched by Cellectis SA on the Alternext market of the Paris Euronext stock exchange in January has been successfully completed and generated gross proceeds of €21.2 million (US$27.5 million)
The offer price was set at €10.25 per share, at the very top of the indicative price bracket (€8.90-€10.25), and the 15 percent extension option was exercised in full. If the additional 15 percent over allotment option also is exercised in full, gross proceeds will rise to €24.4 million.
About 25.3 percent of the company's capital is now in free float, and that will rise to 28.1 percent if the greenshoe is fully taken up.
The shares reserved for institutional investors were six times oversubscribed, and those offered to individual investors more than five times oversubscribed. According to CFO Marc Le Boze, almost four-fifths of the demand for shares came from France, 8.5 percent from the U.K., 7 percent from Scandinavia and 5 percent from Germany and Switzerland.